Analysts Set 10x Genomics, Inc. (NASDAQ:TXG) Target Price at $20.21

10x Genomics, Inc. (NASDAQ:TXG) has received an average rating of “Hold” from the seventeen analysts that are presently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, nine have given a hold rating and seven have issued a buy rating on the company. The average twelve-month target price among brokers that have covered the stock in the last year is $20.21.

A number of research firms recently weighed in on TXG. Leerink Partners lowered shares of 10x Genomics from an “outperform” rating to a “market perform” rating and reduced their price objective for the company from $25.00 to $12.00 in a research note on Thursday, February 13th. Stifel Nicolaus reduced their price objective on shares of 10x Genomics from $21.00 to $18.00 and set a “buy” rating for the company in a research note on Thursday, February 13th. Barclays reduced their price objective on shares of 10x Genomics from $19.00 to $18.00 and set an “overweight” rating for the company in a research note on Monday, February 10th. Weiss Ratings reiterated a “sell (e+)” rating on shares of 10x Genomics in a research note on Friday, March 7th. Finally, Canaccord Genuity Group reduced their price objective on shares of 10x Genomics from $20.00 to $18.00 and set a “buy” rating for the company in a research note on Thursday, February 13th.

10x Genomics Trading Up 4.4 %

NASDAQ:TXG opened at $10.39 on Friday. The stock has a market capitalization of $1.27 billion, a PE ratio of -6.84 and a beta of 1.93. The firm’s 50 day moving average is $12.68 and its 200 day moving average is $15.53. 10x Genomics has a 12 month low of $9.27 and a 12 month high of $38.49.

10x Genomics (NASDAQ:TXG) last posted its quarterly earnings results on Wednesday, February 12th. The company reported ($0.40) EPS for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.08). 10x Genomics had a negative return on equity of 25.40% and a negative net margin of 29.90%. Research analysts predict that 10x Genomics will post -1.43 earnings per share for the current year.

Insider Transactions at 10x Genomics

In other 10x Genomics news, CEO Serge Saxonov sold 5,092 shares of the business’s stock in a transaction on Monday, February 24th. The shares were sold at an average price of $11.07, for a total value of $56,368.44. Following the completion of the sale, the chief executive officer now directly owns 879,482 shares of the company’s stock, valued at $9,735,865.74. The trade was a 0.58 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Alan Mateo purchased 40,000 shares of the stock in a transaction on Friday, February 21st. The stock was acquired at an average cost of $11.14 per share, with a total value of $445,600.00. Following the completion of the purchase, the director now directly owns 61,691 shares of the company’s stock, valued at $687,237.74. The trade was a 184.41 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 10.03% of the stock is currently owned by insiders.

Institutional Trading of 10x Genomics

Several hedge funds have recently added to or reduced their stakes in the business. KBC Group NV lifted its stake in 10x Genomics by 38.8% in the third quarter. KBC Group NV now owns 3,225 shares of the company’s stock worth $73,000 after purchasing an additional 902 shares during the last quarter. Atria Wealth Solutions Inc. lifted its stake in 10x Genomics by 9.6% in the fourth quarter. Atria Wealth Solutions Inc. now owns 10,788 shares of the company’s stock worth $155,000 after purchasing an additional 943 shares during the last quarter. First Horizon Advisors Inc. lifted its stake in 10x Genomics by 53.3% in the third quarter. First Horizon Advisors Inc. now owns 2,910 shares of the company’s stock worth $66,000 after purchasing an additional 1,012 shares during the last quarter. Blue Trust Inc. raised its stake in shares of 10x Genomics by 73.1% during the fourth quarter. Blue Trust Inc. now owns 3,075 shares of the company’s stock valued at $44,000 after acquiring an additional 1,299 shares during the last quarter. Finally, Sound Income Strategies LLC raised its stake in shares of 10x Genomics by 65.2% during the fourth quarter. Sound Income Strategies LLC now owns 3,370 shares of the company’s stock valued at $48,000 after acquiring an additional 1,330 shares during the last quarter. 84.68% of the stock is owned by institutional investors.

10x Genomics Company Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.